Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy

The Lancet Infectious Diseases

Volumn 17, Issue 6, 2017, Pages e177-e188

  Rawlinson, William D ^a,b   Boppana, Suresh B ^c   Fowler, Karen B ^c   Kimberlin, David W ^c   Lazzarotto, Tiziana ^d   Alain, Sophie ^e   Daly, Kate ^f   Doutré, Sara ^g   Gibson, Laura ^h   Giles, Michelle L ⁱ   Greenlee, Janelle ^g   Hamilton, Stuart T ^a   Harrison, Gail J ^j   Hui, Lisa ^k,l   Jones, Cheryl A ^m,o   Palasanthiran, Pamela ^b,p   Schleiss, Mark R ^q   Shand, Antonia W ^n,r   van Zuylen, Wendy J ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF LIMOGES   (France)

^f Congenital Cytomegalovirus Association ^*  (Australia)

^g National Cytomegalovirus Foundation   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ MONASH UNIVERSITY   (Australia)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k MERCY HOSPITAL FOR WOMEN   (Australia)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m University of Sydney   (Australia)

ⁿ UNIVERSITY OF SYDNEY   (Australia)

^o CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^p SYDNEY CHILDREN'S HOSPITAL   (Australia)

^q UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^r ROYAL HOSPITAL FOR WOMEN   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; VALGANCICLOVIR;

ANTIVIRAL THERAPY; CONGENITAL INFECTION; CONSENSUS DEVELOPMENT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEVELOPMENTAL DELAY; HUMAN; NEWBORN SCREENING; PERCEPTION DEAFNESS; PRACTICE GUIDELINE; PREGNANCY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VERTICAL TRANSMISSION; CONGENITAL ABNORMALITIES; CONSENSUS; CYTOMEGALOVIRUS INFECTIONS; DEVELOPMENTAL DISABILITIES; FEMALE; HEARING LOSS, SENSORINEURAL; ISOLATION AND PURIFICATION; MOTHER; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; TRANSMISSION; VIROLOGY;

CONGENITAL ABNORMALITIES; CONSENSUS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DEVELOPMENTAL DISABILITIES; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 85014810347     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30143-3     Document Type: Review

References (139)

1. Mussi-Pinhata, MM, Yamamoto, AY, Moura Brito, RM, et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis 49 (2009), 522–528.
2. Kenneson, A, Cannon, MJ, Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17 (2007), 253–276.
3. Manicklal, S, Emery, VC, Lazzarotto, T, Boppana, SB, Gupta, RK, The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev 26 (2013), 86–102.
4. Hamilton, ST, van Zuylen, W, Shand, A, et al. Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: a systematic review. Rev Med Virol 24 (2014), 420–433.
5. Korver, AM, Konings, S, Dekker, FW, et al. Newborn hearing screening vs later hearing screening and developmental outcomes in children with permanent childhood hearing impairment. JAMA 304 (2010), 1701–1708.
6. Kimberlin, DW, Jester, PM, Sanchez, PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 372 (2015), 933–943.
7. Demmler-Harrison, GJ, Congenital cytomegalovirus: Public health action towards awareness, prevention, and treatment. J Clin Virol 46:suppl 4 (2009), S1–S5.
8. Hawaii State Legislation. Hawaii House Bill 782. https://legiscan.com/HI/text/HB782/2015, 2015 (accessed Feb 10, 2017).
9. Utah Department of Health. Cytomegalovirus (CMV) public health initiative. http://health.utah.gov/cshcn/programs/cmv.html (accessed Feb 10, 2017).
10. Texas State Legislation. Texas Senate Bill 791. https://legiscan.com/TX/bill/SB791/2015, 2015 (accessed Feb 10, 2017).
11. Kotton, CN, Kumar, D, Caliendo, AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89 (2010), 779–795.
12. Nachman, S, Ahmed, A, Amanullah, F, et al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis 15 (2015), 711–720.
13. Mallet, V, van Bommel, F, Doerig, C, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 16 (2016), 606–617.
14. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence. http://www.cebm.net/index.aspx?o=5653 (accessed Feb 10, 2017).
15. Forsgren, M, Prevention of congenital and perinatal infections. Euro Surveill 14 (2009), 2–4.
16. Rahav, G, Congenital cytomegalovirus infection—a question of screening. Isr Med Assoc J 9 (2007), 392–394.
17. Doutre, S, Reducing congenital cytomegalovirus infection through policy and legislation in the United States. Microbiology Australia, 2015, 162–164 November.
18. Walker, SP, Palma-Dias, R, Wood, EM, Shekleton, P, Giles, ML, Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy Childbirth, 13, 2013, 96.
19. Pass, RF, Fowler, KB, Boppana, SB, Britt, WJ, Stagno, S, Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J Clin Virol 35 (2006), 216–220.
20. Adler, SP, Finney, JW, Manganello, AM, Best, AM, Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial. Pediatr Infect Dis J 15 (1996), 240–246.
21. Revello, MG, Tibaldi, C, Masuelli, G, et al. Prevention of primary cytomegalovirus infection in pregnancy. EBioMedicine 2 (2015), 1205–1210.
22. Vauloup-Fellous, C, Picone, O, Cordier, AG, et al. Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital. J Clin Virol 46:suppl 4 (2009), S49–S53.
23. Adler, SP, Finney, JW, Manganello, AM, Best, AM, Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J Pediatr 145 (2004), 485–491.
24. Adler, SP, Cytomegalovirus and child day care: risk factors for maternal infection. Pediatr Infect Dis J 10 (1991), 590–594.
25. Walmus, BF, Yow, MD, Lester, JW, Leeds, L, Thompson, PK, Woodward, RM, Factors predictive of cytomegalovirus immune status in pregnant women. J Infect Dis 157 (1988), 172–177.
26. Taber, LH, Frank, AL, Yow, MD, Bagley, A, Acquisition of cytomegaloviral infections in families with young children: a serological study. J Infect Dis 151 (1985), 948–952.
27. Stagno, S, Cloud, G, Pass, RF, Britt, WJ, Alford, CA, Factors associated with primary cytomegalovirus infection during pregnancy. J Med Virol 13 (1984), 347–353.
28. Stagno, S, Pass, RF, Dworsky, ME, et al. Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N Engl J Med 306 (1982), 945–949.
29. Wang, C, Zhang, X, Bialek, S, Cannon, MJ, Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis 52 (2011), e11–e13.
30. Townsend, CL, Forsgren, M, Ahlfors, K, Ivarsson, SA, Tookey, PA, Peckham, CS, Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin Infect Dis 56 (2013), 1232–1239.
31. Boppana, SB, Rivera, LB, Fowler, KB, Mach, M, Britt, WJ, Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 344 (2001), 1366–1371.
32. Ross, SA, Arora, N, Novak, Z, Fowler, KB, Britt, WJ, Boppana, SB, Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201 (2010), 386–389.
33. Yamamoto, AY, Mussi-Pinhata, MM, Boppana, SB, et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol, 202, 2010, 297 e1 297 e8.
34. Ornoy, A, Diav-Citrin, O, Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. Reprod Toxicol 21 (2006), 399–409.
35. Yamamoto, AY, Mussi-Pinhata, MM, Isaac Mde, L, et al. Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population. Pediatr Infect Dis J 30 (2011), 1043–1046.
36. Ahlfors, K, Ivarsson, SA, Harris, S, Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. Scand J Infect Dis 31 (1999), 443–457.
37. Gaytant, MA, Rours, GI, Steegers, EA, Galama, JM, Semmekrot, BA, Congenital cytomegalovirus infection after recurrent infection: case reports and review of the literature. Eur J Pediatr 162 (2003), 248–253.
38. Zalel, Y, Gilboa, Y, Berkenshtat, M, et al. Secondary cytomegalovirus infection can cause severe fetal sequelae despite maternal preconceptional immunity. Ultrasound Obstet Gynecol 31 (2008), 417–420.
39. Boppana, SB, Fowler, KB, Britt, WJ, Stagno, S, Pass, RF, Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 104 (1999), 55–60.
40. Ross, SA, Fowler, KB, Ashrith, G, et al. Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J Pediatr 148 (2006), 332–336.
41. Nigro, G, Anceschi, MM, Cosmi, EV, Clinical manifestations and abnormal laboratory findings in pregnant women with primary cytomegalovirus infection. BJOG 110 (2003), 572–577.
42. Revello, MG, Gerna, G, Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 15 (2002), 680–715.
43. Munro, SC, Hall, B, Whybin, LR, et al. Diagnosis of and screening for cytomegalovirus infection in pregnant women. J Clin Microbiol 43 (2005), 4713–4718.
44. Lazzarotto, T, Varani, S, Spezzacatena, P, et al. Maternal IgG avidity and IgM detected by blot as diagnostic tools to identify pregnant women at risk of transmitting cytomegalovirus. Viral Immunol 13 (2000), 137–141.
45. Mace, M, Sissoeff, L, Rudent, A, Grangeot-Keros, L, A serological testing algorithm for the diagnosis of primary CMV infection in pregnant women. Prenat Diagn 24 (2004), 861–863.
46. Lazzarotto, T, Guerra, B, Gabrielli, L, Lanari, M, Landini, MP, Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. Clin Microbiol Infect 17 (2011), 1285–1293.
47. Prince, HE, Lape-Nixon, M, Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy. Clin Vaccine Immunol 21 (2014), 1377–1384.
48. Rajasekariah, H, Scott, G, Robertson, PW, Rawlinson, WD, Improving diagnosis of primary cytomegalovirus infection in pregnant women using immunoblots. J Med Virol 85 (2013), 315–319.
49. Enders, G, Daiminger, A, Bader, U, Exler, S, Schimpf, Y, Enders, M, The value of CMV IgG avidity and immunoblot for timing the onset of primary CMV infection in pregnancy. J Clin Virol 56 (2013), 102–107.
50. Salomon, LJ, Bernard, JP, Millischer, AE, et al. MRI and ultrasound fusion imaging for prenatal diagnosis. Am J Obstet Gynecol, 209, 2013, 148 e1 148 e9.
51. Wulff, CB, Gerds, TA, Rode, L, Ekelund, CK, Petersen, OB, Tabor, A, Risk of fetal loss associated with invasive testing following combined first-trimester screening for Down syndrome: a national cohort of 147,987 singleton pregnancies. Ultrasound Obstet Gynecol 47 (2016), 38–44.
52. Liesnard, C, Donner, C, Brancart, F, Gosselin, F, Delforge, ML, Rodesch, F, Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk. Obstet Gynecol 95 (2000), 881–888.
53. Donner, C, Liesnard, C, Brancart, F, Rodesch, F, Accuracy of amniotic fluid testing before 21 weeks’ gestation in prenatal diagnosis of congenital cytomegalovirus infection. Prenat Diagn 14 (1994), 1055–1059.
54. Revello, MG, Gerna, G, Pathogenesis and prenatal diagnosis of human cytomegalovirus infection. J Clin Virol 29 (2004), 71–83.
55. Azam, AZ, Vial, Y, Fawer, CL, Zufferey, J, Hohlfeld, P, Prenatal diagnosis of congenital cytomegalovirus infection. Obstet Gynecol 97 (2001), 443–448.
56. Lazzarotto, T, Varani, S, Guerra, B, Nicolosi, A, Lanari, M, Landini, MP, Prenatal indicators of congenital cytomegalovirus infection. J Pediatr 137 (2000), 90–95.
57. Guerra, B, Lazzarotto, T, Quarta, S, et al. Prenatal diagnosis of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol 183 (2000), 476–482.
58. Leruez-Ville, M, Stirnemann, J, Sellier, Y, et al. Feasibility of predicting the outcome of fetal infection with cytomegalovirus at the time of prenatal diagnosis. Am J Obstet Gynecol, 215, 2016, 342 e1 342 e9.
59. Farkas, N, Hoffmann, C, Ben-Sira, L, et al. Does normal fetal brain ultrasound predict normal neurodevelopmental outcome in congenital cytomegalovirus infection?. Prenat Diagn 31 (2011), 360–366.
60. Guerra, B, Simonazzi, G, Puccetti, C, et al. Ultrasound prediction of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol, 198, 2008, 380 e1 380 e7.
61. Benoist, G, Salomon, LJ, Jacquemard, F, Daffos, F, Ville, Y, The prognostic value of ultrasound abnormalities and biological parameters in blood of fetuses infected with cytomegalovirus. BJOG 115 (2008), 823–829.
62. Alarcon, A, Martinez-Biarge, M, Cabanas, F, Quero, J, Garcia-Alix, A, A prognostic neonatal neuroimaging scale for symptomatic congenital cytomegalovirus infection. Neonatology 110 (2016), 277–285.
63. Picone, O, Simon, I, Benachi, A, Brunelle, F, Sonigo, P, Comparison between ultrasound and magnetic resonance imaging in assessment of fetal cytomegalovirus infection. Prenat Diagn 28 (2008), 753–758.
64. Lipitz, S, Hoffmann, C, Feldman, B, Tepperberg-Dikawa, M, Schiff, E, Weisz, B, Value of prenatal ultrasound and magnetic resonance imaging in assessment of congenital primary cytomegalovirus infection. Ultrasound Obstet Gynecol 36 (2010), 709–717.
65. Revello, MG, Zavattoni, M, Furione, M, Baldanti, F, Gerna, G, Quantification of human cytomegalovirus DNA in amniotic fluid of mothers of congenitally infected fetuses. J Clin Microbiol 37 (1999), 3350–3352.
66. Goegebuer, T, Van Meensel, B, Beuselinck, K, et al. Clinical predictive value of real-time PCR quantification of human cytomegalovirus DNA in amniotic fluid samples. J Clin Microbiol 47 (2009), 660–665.
67. Grazia Revello, M, Zavattoni, M, Sarasini, A, et al. Prenatal diagnostic and prognostic value of human cytomegalovirus load and IgM antibody response in blood of congenitally infected fetuses. J Infect Dis 180 (1999), 1320–1323.
68. Romanelli, RM, Magny, JF, Jacquemard, F, Prognostic markers of symptomatic congenital cytomegalovirus infection. Braz J Infect Dis 12 (2008), 38–43.
69. Desveaux, C, Klein, J, Leruez-Ville, M, et al. Identification of symptomatic fetuses infected with cytomegalovirus using amniotic fluid peptide biomarkers. PLoS Pathog, 12, 2016, e1005395.
70. Fabbri, E, Revello, MG, Furione, M, et al. Prognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood. BJOG 118 (2011), 448–456.
71. Gerber, S, Vial, Y, Hohlfeld, P, Witkin, SS, Prenatal diagnosis of congenital cytomegalovirus infection by detection of immunoglobulin M antibodies to the 70-kd heat shock protein in fetal serum. Am J Obstet Gynecol 187 (2002), 955–959.
72. Enders, G, Bader, U, Lindemann, L, Schalasta, G, Daiminger, A, Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome. Prenat Diagn 21 (2001), 362–377.
73. Pass, RF, Zhang, C, Evans, A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360 (2009), 1191–1199.
74. Bernstein, DI, Munoz, FM, Callahan, ST, et al. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial. Vaccine 34 (2016), 313–319.
75. Grosjean, J, Trapes, L, Hantz, S, et al. Human cytomegalovirus quantification in toddlers saliva from day care centers and emergency unit: a feasibility study. J Clin Virol 61 (2014), 371–377.
76. Stowell, JD, Forlin-Passoni, D, Din, E, et al. Cytomegalovirus survival on common environmental surfaces: opportunities for viral transmission. J Infect Dis 205 (2012), 211–214.
77. Stowell, JD, Forlin-Passoni, D, Radford, K, et al. Cytomegalovirus survival and transferability and the effectiveness of common hand-washing agents against cytomegalovirus on live human hands. Appl Environ Microbiol 80 (2014), 455–461.
78. Cannon, MJ, Stowell, JD, Clark, R, et al. Repeated measures study of weekly and daily cytomegalovirus shedding patterns in saliva and urine of healthy cytomegalovirus-seropositive children. BMC Infect Dis, 14, 2014, 569.
79. Harvey, J, Dennis, CL, Hygiene interventions for prevention of cytomegalovirus infection among childbearing women: systematic review. J Adv Nurs 63 (2008), 440–450.
80. Lim, SL, Tan, WC, Tan, LK, Awareness of and attitudes toward congenital cytomegalovirus infection among pregnant women in Singapore. Int J Gynaecol Obstet 117 (2012), 268–272.
81. Jeon, J, Victor, M, Adler, SP, et al. Knowledge and awareness of congenital cytomegalovirus among women. Infect Dis Obstet Gynecol, 2006, 2006, 80383.
82. Pereboom, MT, Mannien, J, Spelten, ER, Schellevis, FG, Hutton, EK, Observational study to assess pregnant women's knowledge and behaviour to prevent toxoplasmosis, listeriosis and cytomegalovirus. BMC Pregnancy Childbirth, 13, 2013, 98.
83. Cannon, MJ, Westbrook, K, Levis, D, Schleiss, MR, Thackeray, R, Pass, RF, Awareness of and behaviors related to child-to-mother transmission of cytomegalovirus. Prev Med 54 (2012), 351–357.
84. Morioka, I, Sonoyama, A, Tairaku, S, et al. Awareness of and knowledge about mother-to-child infections in Japanese pregnant women. Congenit Anom (Kyoto) 54 (2014), 35–40.
85. Willame, A, Blanchard-Rohner, G, Combescure, C, Irion, O, Posfay-Barbe, K, Martinez de Tejada, B, Awareness of cytomegalovirus infection among pregnant women in Geneva, Switzerland: a cross-sectional study. Int J Environ Res Public Health 12 (2015), 15285–15297.
86. Wizman, S, Lamarre, V, Coic, L, et al. Awareness of cytomegalovirus and risk factors for susceptibility among pregnant women, in Montreal, Canada. BMC Pregnancy Childbirth, 16, 2016, 54.
87. Baer, HR, McBride, HE, Caviness, AC, Demmler-Harrison, GJ, Survey of congenital cytomegalovirus (cCMV) knowledge among medical students. J Clin Virol 60 (2014), 222–242.
88. Korver, AM, de Vries, JJ, de Jong, JW, Dekker, FW, Vossen, AC, Oudesluys-Murphy, AM, Awareness of congenital cytomegalovirus among doctors in the Netherlands. J Clin Virol 46:suppl 4 (2009), S11–S15.
89. Cordier, AG, Guitton, S, Vauloup-Fellous, C, Grangeot-Keros, L, Benachi, A, Picone, O, Awareness and knowledge of congenital cytomegalovirus infection among health care providers in France. J Clin Virol 55 (2012), 158–163.
90. von Gartzen, A, Hollins Martin, CJ, An email survey of midwives knowledge about CytoMegaloVirus (CMV) in Hannover and a skeletal framework for a proposed teaching program. Nurse Educ Pract 13 (2013), 481–486.
91. de Vries, JJ, van Zwet, EW, Dekker, FW, Kroes, AC, Verkerk, PH, Vossen, AC, The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Rev Med Virol 23 (2013), 241–249.
92. Nigro, G, Adler, SP, La Torre, R, Best, AM, Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353 (2005), 1350–1362.
93. Revello, MG, Lazzarotto, T, Guerra, B, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370 (2014), 1316–1326.
94. Buxmann, H, Stackelberg, OM, Schlosser, RL, et al. Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis. J Perinat Med 40 (2012), 439–446.
95. Nigro, G, Capretti, I, Manganello, AM, Best, AM, Adler, SP, Primary maternal cytomegalovirus infections during pregnancy: association of CMV hyperimmune globulin with gestational age at birth and birth weight. J Matern Fetal Neonatal Med 28 (2015), 1–4.
96. Hamprecht, K, Kagan, KO, Goelz, R, Hyperimmune globulin to prevent congenital CMV infection. N Engl J Med, 370, 2014, 2543.
97. Jacquemard, F, Yamamoto, M, Costa, JM, et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG 114 (2007), 1113–1121.
98. Nigro, G, Adler, SP, Parruti, G, et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy—a case-control study of the outcome in children. J Infect Dis 205 (2012), 215–227.
99. Visentin, S, Manara, R, Milanese, L, et al. Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis 55 (2012), 497–503.
100. Japanese Congenital Cytomegalovirus Infection Immunoglobulin Fetal Therapy Study Group. A trial of immunoglobulin fetal therapy for symptomatic congenital cytomegalovirus infection. J Reprod Immunol 95 (2012), 73–79.
101. Nigro, G, Adler, SP, Gatta, E, et al. Fetal hyperechogenic bowel may indicate congenital cytomegalovirus disease responsive to immunoglobulin therapy. J Matern Fetal Neonatal Med 25 (2012), 2202–2205.
102. Alvarez-McLeod, A, Havlik, J, Drew, KE, Foscarnet treatment of genital infection due to acyclovir-resistant herpes simplex virus type 2 in a pregnant patient with AIDS: case report. Clin Infect Dis 29 (1999), 937–938.
103. Puliyanda, DP, Silverman, NS, Lehman, D, et al. Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient. Transpl Infect Dis 7 (2005), 71–74.
104. Brandy, RC, Schleiss, MR, Witte, DP, Siddiqi, TA, Fame, PT, Placental transfer of ganciclovir in a woman with acquired immunodeficiency syndrome and cytomegalovirus disease. Pediatr Infect Dis J 21 (2002), 796–797.
105. Miller, BW, Howard, TK, Goss, JA, Mostello, DJ, Holcomb, WL Jr, Brennan, DC, Renal transplantation one week after conception. Transplantation 60 (1995), 1353–1354.
106. Pescovitz, MD, Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient. Transplantation 67 (1999), 758–759.
107. Lowance, D, Neumayer, HH, Legendre, CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 340 (1999), 1462–1470.
108. Ratanajamit, C, Vinther Skriver, M, Jepsen, P, Chongsuvivatwong, V, Olsen, J, Sorensen, HT, Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study. Scand J Infect Dis 35 (2003), 255–259.
109. Wilton, LV, Pearce, GL, Martin, RM, Mackay, FJ, Mann, RD, The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gyncaecol 105 (1998), 882–889.
110. Stone, KM, Reiff-Eldridge, R, White, AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol 70 (2004), 201–207.
111. Pasternak, B, Hviid, A, Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 304 (2010), 859–866.
112. Leruez-Ville, M, Ghout, I, Bussieres, L, et al. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Am J Obstet Gynecol 215 (2016), 462 e1–462462.
113. Goderis, J, De Leenheer, E, Smets, K, Van Hoecke, H, Keymeulen, A, Dhooge, I, Hearing loss and congenital CMV infection: a systematic review. Pediatrics 134 (2014), 972–982.
114. Cannon, MJ, Griffiths, PD, Aston, V, Rawlinson, WD, Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit?. Rev Med Virol 24 (2014), 291–307.
115. Kennedy, CR, McCann, DC, Campbell, MJ, et al. Language ability after early detection of permanent childhood hearing impairment. N Engl J Med 354 (2006), 2131–2141.
116. Williams, EJ, Gray, J, Luck, S, et al. First estimates of the potential cost and cost saving of protecting childhood hearing from damage caused by congenital CMV infection. Arch Dis Child Fetal Neonatal Ed 100 (2015), F501–F506.
117. Nishida, K, Morioka, I, Nakamachi, Y, et al. Neurological outcomes in symptomatic congenital cytomegalovirus-infected infants after introduction of newborn urine screening and antiviral treatment. Brain Dev 38 (2016), 209–216.
118. Bergevin, A, Zick, CD, McVicar, SB, Park, AH, Cost-benefit analysis of targeted hearing directed early testing for congenital cytomegalovirus infection. Int J Pediatr Otorhinolaryngol 79 (2015), 2090–2093.
119. Gantt, S, Dionne, F, Kozak, FK, et al. Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection. JAMA Pediatr 170 (2016), 1173–1180.
120. Barkai, G, Ari-Even Roth, D, Barzilai, A, et al. Universal neonatal cytomegalovirus screening using saliva–report of clinical experience. J Clin Virol 60 (2014), 361–366.
121. Kadambari, S, Luck, S, Davis, A, et al. Evaluating the feasibility of integrating salivary testing for congenital CMV into the newborn hearing screening programme in the UK. Eur J Pediatr 174 (2015), 1117–1121.
122. Koyano, S, Inoue, N, Oka, A, et al. Screening for congenital cytomegalovirus infection using newborn urine samples collected on filter paper: feasibility and outcomes from a multicentre study. BMJ Open, 1, 2011, e000118.
123. Boppana, SB, Ross, SA, Novak, Z, et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA 303 (2010), 1375–1382.
124. Koontz, D, Baecher, K, Amin, M, Nikolova, S, Gallagher, M, Dollard, S, Evaluation of DNA extraction methods for the detection of Cytomegalovirus in dried blood spots. J Clin Virol 66 (2015), 95–99.
125. Yamamoto, AY, Mussi-Pinhata, MM, Marin, LJ, Brito, RM, Oliveira, PF, Coelho, TB, Is saliva as reliable as urine for detection of cytomegalovirus DNA for neonatal screening of congenital CMV infection?. J Clin Virol 36 (2006), 228–230.
126. Boppana, SB, Ross, SA, Shimamura, M, et al. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med 364 (2011), 2111–2118.
127. Hamprecht, K, Maschmann, J, Vochem, M, Dietz, K, Speer, CP, Jahn, G, Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 357 (2001), 513–518.
128. Dworsky, M, Yow, M, Stagno, S, Pass, RF, Alford, C, Cytomegalovirus infection of breast milk and transmission in infancy. Pediatrics 72 (1983), 295–299.
129. Koyano, S, Inoue, N, Nagamori, T, Moriuchi, H, Azuma, H, Newborn screening of congenital cytomegalovirus infection using saliva can be influenced by breast feeding. Arch Dis Child Fetal Neonatal Ed, 98, 2013, F182.
130. Whitley, RJ, Cloud, G, Gruber, W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 175 (1997), 1080–1086.
131. Kimberlin, DW, Lin, CY, Sanchez, PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 143 (2003), 16–25.
132. Oliver, SE, Cloud, GA, Sanchez, PJ, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol 46:suppl 4 (2009), S22–S26.
133. Michaels, MG, Greenberg, DP, Sabo, DL, Wald, ER, Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr Infect Dis J 22 (2003), 504–509.
134. Tanaka-Kitajima, N, Sugaya, N, Futatani, T, et al. Ganciclovir therapy for congenital cytomegalovirus infection in six infants. Pediatr Infect Dis J 24 (2005), 782–785.
135. Nigro, G, Scholz, H, Bartmann, U, Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience. J Pediatr 124 (1994), 318–322.
136. Lackner, A, Acham, A, Alborno, T, et al. Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up. J Laryngol Otol 123 (2009), 391–396.
137. Lombardi, G, Garofoli, F, Villani, P, et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 28 (2009), 1465–1470.
138. del Rosal, T, Baquero-Artigao, F, Blazquez, D, et al. Treatment of symptomatic congenital cytomegalovirus infection beyond the neonatal period. J Clin Virol 55 (2012), 72–74.
139. Kimberlin, DW, Acosta, EP, Sanchez, PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 197 (2008), 836–845.